Treatment of lupus nephritis and primary glomerulonephritis with enteric-coated mycophenolate sodium

Clinical Nephrology

Volumn 69, Issue 2, 2008, Pages 90-101

  Kitiyakara, C ^a   Ophascharoensuk, V ^b   Changsirikulchai, S ^c   Ingsathit, A ^a   Tankee, P ^a   Sangpanich, A ^c   Sumethkul, V ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

Glomerular; Kidney; Lupus; Myfortic; Nephritis; Nephrotic; Proteinuria

Indexed keywords

ACICLOVIR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN; LOSARTAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; TELMISARTAN; TUBERCULOSTATIC AGENT; VALSARTAN;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CELLULITIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; FOCAL GLOMERULONEPHRITIS; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; HEMATOCRIT; HERPES ZOSTER; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; MONOTHERAPY; PNEUMONIA; PROTEINURIA; REMISSION; SEPSIS; SEPTICEMIA; SIDE EFFECT; TUBERCULOUS MENINGITIS;

EID: 38949161453     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP69090     Document Type: Article

References (27)

1. Bagga A et al. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis. 2003; 42: 1114-1120.
2. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus. 1998; 7: 622-629.
3. Budde K et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004a; 4: 237-243.
4. Budde K et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Exp Opin Pharmacother. 2004b; 5: 1333-1345.
5. Budde K et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol. 2006; 66: 103-111.
6. Chan L et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation. 2006; 81: 1290-1297.
7. Chan TM et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000; 343: 1156-1162.
8. Choi MJ et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002; 61: 1098-1114.
9. Churg J et al. Renal disease: classification and atlas of glomerular diseases (2nd ed). New York: Igaku-Shoin;1995.
10. Contreras G et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004; 350: 971-980.
11. Day CJ et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2002; 17: 2011-2013.
12. Dooley MA et al. 1999. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol. 10: 833-839.
13. Frisch G et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind, randomized controlled trial. Nephrol Dial Transplant. 2005; 20: 2139-2145.
14. Ginzler EM et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005; 3 n53: 2219-228.
15. Group EMMCS. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995; 345: 1321-1325.
16. Illei GG et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse Immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002; 46: 995-1002.
17. Kitiyakara C et al. 21-year trend in ESRD due to focal segmental glomeruloselerosis in the United States. Am J Kidney Dis. 2004; 44: 815-825.
18. Korbet SM et al. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis. 1994; 23: 773-783.
19. Levey AS et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
20. Maes BD et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-1849.
21. Miller G et al. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis. 2000; 36: 250-256.
22. Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum. 2006; 36: 71-81.
23. Salvadori M et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS, myfortic) is safe in kidney transplant patients. Clin Nephrol. 2006; 66: 112-119.
24. Salvadori M et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004; 4: 231-236.
25. Spetie DN et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 2004; 66: 2411-2415.
26. Tang S et al. Mycophenolate mofetil in the treatment of steroid-resistant primary focal segmental glomerulosclerosis. J Nephrol. 2005a; 18: 429-432.
27. Tang S et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005b; 68: 802-912.